Koky Sang
Internal Medicine · Flushing, NYNPI 1821294273
Payments from drug & device makers
Across 122 payments — averaging $51.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Novo Nordisk$751
- Amgen$579
- Amarin Pharma, Inc.$409
- Lilly USA, LLC$399
- Teva Pharmaceuticals USA, Inc.$375
- plus $1K from 10 others
What the payments were for
- Food & beverage$6,292100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 69 | $2,411 |
| Novo Nordisk | 12 | $751 |
| Amgen | 6 | $579 |
| Amarin Pharma, Inc. | 5 | $409 |
| Lilly USA, LLC | 10 | $399 |
| Teva Pharmaceuticals USA, Inc. | 3 | $375 |
| Boehringer Ingelheim | 5 | $283 |
| AbbVie(2 entities) | 3 | $273 |
| Neurocrine Biosciences, Inc. | 2 | $250 |
| Sanofi | 1 | $146 |
| AstraZeneca | 1 | $125 |
| Merck | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Pfizer | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,300 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $107,129 |
| JanuviaSitagliptin Phosphate | 74 | $73,574 |
| VascepaIcosapent Ethyl | 108 | $68,410 |
| Diclofenac Epolamine | 46 | $34,182 |
| RybelsusSemaglutide | 15 | $28,707 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $19,146 |
| MyrbetriqMirabegron | 15 | $10,502 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $6,117 |
| Atorvastatin Calcium | 435 | $3,751 |
| Omega-3 Acid Ethyl Esters | 16 | $3,253 |
| Raloxifene Hcl | 96 | $2,966 |
| Amlodipine Besylate | 323 | $1,845 |
| Losartan Potassium | 232 | $1,803 |
| Nateglinide | 31 | $1,407 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $283 | $107,129112 claims |
| MerckJanuvia, Janumet | $125 | $92,72091 claims |
| Novo NordiskRybelsus | $751 | $28,70715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.